Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
16 août 2021 08h15 HE
|
Vaccinex, Inc.
Patients are currently being screened and enrolled in two studies of pepinemab as monotherapy in Alzheimer’s disease and in combination with KEYTRUDA® in Metastatic Head and Neck Squamous Cell...
Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease
30 juin 2021 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 30, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
08 juin 2021 07h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference
19 mai 2021 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
17 mai 2021 08h15 HE
|
Vaccinex, Inc.
Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck cancer Announced publication of results from CLASSICAL-Lung phase 1b/2 clinical...
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
21 avr. 2021 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 21, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
16 mars 2021 08h05 HE
|
Vaccinex, Inc.
Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab in neurodegenerative disease. New Alzheimer’s study expected to begin enrollment in Q2 ...
Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference
11 mars 2021 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 11, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology
22 févr. 2021 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform
19 févr. 2021 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...